Home » Newsletters » BioWorld Science

BioWorld Science

April 24, 2019

View Archived Issues

Parkinson's drug inhibits obesity gene

Novel mouse model of human acute myeloid leukemia with autologous immune system

Researchers create animal model of orthopedic injury-induced hypercoagulability

Identification of selective, orally active RORgammat inverse agonists

Positive initial phase II data for nomacopan in bullous pemphigoid

Tracon Pharmaceuticals initiates phase I study of TJ-004309 in combination with atezolizumab

New blood test developed for early Alzheimer's diagnosis

Yuhan presents preclinical data for its novel anti-TIGIT antibody, YH-29143

Sunshine Lake Pharma divulges 5-HT1A receptor agonists

Nanjing TransThera Biosciences patents PDE9 inhibitors

Preclinical characterization of humanized anti-MERTK monoclonal antibody, RGX-019

MGL inhibitors revealed in Takeda Pharmaceutical patent

Phase I data reported for RO-7049389 in patients with chronic HBV infection

MET-409 is safe and well tolerated in phase I study in healthy male subjects

Beijing Yuezhikangtai Biomedicines identifies hedgehog-signaling inhibitors

Fujifilm presents new antibacterials

Preclinical characterization detailed for phase I cancer candidate S-64315/MIK-665

Takeda communicates data on ART-648 in preclinical models of NASH

Innovent begins phase I trial of PD-1/PD-L1 bispecific antibody IBI-318

Teva discontinues development of fremanezumab for cluster headaches

Tiziana's phase IIa trial of milciclib in advanced liver cancer passes interim safety review

FDA approves Skyrizi for moderate to severe plaque psoriasis

MET/SRC/CSF-1R inhibitor TPX-0022 shows antitumor activity, IND planned

TC BioPharm conducting phase I study of TCB-002 in AML

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...